Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is pioneering the field of synthetic biology by providing an innovative horizontal platform for cell programming. Specializing in flexible, end-to-end services, the company addresses diverse challenges across multiple sectors including food, agriculture, pharmaceuticals, industrial chemicals, and specialty chemicals. Ginkgo Bioworks is organized into two primary segments: Cell Engineering and Biosecurity, with the latter contributing the majority of the company's revenue through data analytics and related services.
One of Ginkgo Bioworks' recent highlights includes the acquisition of AgBiome's platform assets, significantly enhancing its R&D capabilities in agricultural biotechnology. This move has expanded Ginkgo's proprietary metagenomics database, creating a rich resource for AI model development. Furthermore, the company is actively engaged in partnerships to amplify its technological reach, such as its collaboration with Il Granaio delle Idee to enhance sourdough bakery strains and with GreenLab to produce brazzein, a high-intensity sweetener, on a commercial scale.
Ginkgo Bioworks is also a key player in biosecurity, developing advanced infrastructure and technologies to predict, detect, and respond to biological threats. The company's upcoming Biofab1, a fully integrated lab data center expected to open in mid-2025, is part of its strategic plan to streamline operations and achieve adjusted EBITDA breakeven by the end of 2026.
Additionally, Ginkgo's platform is making significant strides in the AI and data generation space, offering services that help clients leverage high-quality data for more effective R&D. Notably, the company recently hosted its 5th annual Ferment conference, where it showcased new products and technological advancements to a global audience.
Despite facing some financial challenges, including a need to regain compliance with NYSE listing standards due to stock price fluctuations, Ginkgo remains committed to its mission. The company continues to innovate and form strategic partnerships, such as its recent agreement with Sojitz Corporation to penetrate the Japanese market, enhancing its role in the global bioeconomy.
For more information, visit ginkgobioworks.com or follow them on social media platforms like X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), and LinkedIn.
Ginkgo Bioworks (NYSE: DNA) has launched its Cell Development Kits (CDKs) service, aimed at simplifying access for aspiring cell developers to program cells for various applications. The initial focus is on protein expression programs, providing essential tools for commercial protein development, starting at $100,000. This service is designed to reduce costs and accelerate timelines, allowing customers to prototype ideas in phases. CEO Jason Kelly emphasized the potential of engineered biology to drive innovation across multiple industries.
Synlogic (SYBX) and Ginkgo Bioworks (DNA) announced the nomination of SYNB1353, an investigational Synthetic Biotic medicine for homocystinuria (HCU). This marks the first product from their collaboration and the first developed on Ginkgo's platform to enter IND-enabling studies. Synlogic aims to file an IND application for SYNB1353 with the FDA in 2022. SYNB1353 is designed to lower plasma homocysteine by metabolizing methionine in the GI tract, providing new treatment options for patients with HCU, a disorder with limited existing therapies.
Ginkgo Bioworks (NYSE: DNA) is set to host a presentation on November 15, 2021, at 8:00 a.m. ET to discuss its third-quarter business performance for the period ending September 30, 2021. Investors can find presentation details and registration on Ginkgo's investor relations website, where a replay will also be available. Questions can be submitted beforehand via Twitter or email. Ginkgo is advancing biotechnology applications in sectors like food, agriculture, and pharmaceuticals, contributing to COVID-19 response efforts such as pooled testing and vaccine optimization.
Ginkgo Bioworks (NYSE: DNA) hosted its annual conference, Ferment, on October 28, 2021, gathering key stakeholders from the synthetic biology ecosystem. The event featured presentations on various topics, including biosecurity, advancements in cell therapies, and the future of synthetic biology. Notable discussions included a keynote from co-founder and CEO Jason Kelly and insights from industry leaders like Arie Belldegrun and Scott Gottlieb. Following the event, videos and additional information will be available on Ginkgo's investor website.
On October 27, 2021, Arcaea, a company launched on the Ginkgo Bioworks platform, announced a $78 million Series A funding round aimed at revolutionizing the beauty industry through innovative biological products. The funding from notable investors like CHANEL and Viking Global will enable Arcaea to develop sustainable beauty ingredients using DNA sequencing and biological engineering. CEO Jasmina Aganovic emphasized the potential of biology as a tool for creative self-expression and sustainability in beauty, aiming to create a new supply chain that avoids petrochemicals.
Selecta Biosciences (Nasdaq: SELB) and Ginkgo Bioworks (NYSE: DNA) have partnered to create innovative enzymes aimed at treating orphan and rare diseases. This collaboration combines Selecta's ImmTOR technology, which has shown success in preclinical and clinical trials, with Ginkgo's advanced enzyme discovery capabilities. Under the agreement, Ginkgo could earn up to $85M in cash for milestone achievements and potential royalties on sales, signaling a promising step towards improving therapeutic options for patients with unmet medical needs.
Quest Diagnostics has entered an agreement with the Texas Department of State Health Services to provide COVID-19 testing services for K-12 schools, benefiting over 1,150 districts in Texas for the 2021-2022 school year. The program utilizes PCR and other nucleic acid amplification tests at Quest's clinical labs. Funding is provided through a CDC grant, ensuring no costs for schools or families. This initiative aims to promote safer in-person learning by enabling pooled testing.
Ginkgo Bioworks Inc. (NYSE: DNA) will present at the Jefferies Gene Therapy/Editing Summit on October 27, 2021, at 3:00 p.m. Eastern Time. The company focuses on a platform for cell programming applicable to various markets, including biotechnology, pharmaceuticals, and industrial chemicals. Ginkgo has also supported COVID-19 initiatives, including vaccine optimization and testing. Investors can access the webcast and presentation replay via the company’s investor relations website.
Ginkgo Bioworks (NYSE: DNA) announced participation in two upcoming conferences. On October 7, 2021, management will attend the Cowen Annual MedTools Conference at 11:15 a.m. ET. Additionally, on October 13, 2021, they will engage in a fireside chat and 1x1 meetings at the Morgan Stanley Annual Spark Conference at 5:45 p.m. ET. For more information, visit their investor relations website.
On September 17, 2021, Ginkgo Bioworks and Soaring Eagle Acquisition Corp. announced the successful closure of their business combination. The newly formed entity, Ginkgo Bioworks Holdings, Inc., will trade on the NYSE under the symbols 'DNA' and 'DNA.WS'. This transaction, approved by Soaring Eagle stockholders on September 14, 2021, yields over $1.6 billion in proceeds and establishes Ginkgo's enterprise value at $15 billion. Ginkgo aims to leverage its cell programming platform to revolutionize various industries and address global challenges.
FAQ
What is the current stock price of Ginkgo Bioworks Holdings (DNA)?
What is the market cap of Ginkgo Bioworks Holdings (DNA)?
What does Ginkgo Bioworks do?
What are the main segments of Ginkgo Bioworks?
What recent acquisitions has Ginkgo Bioworks made?
What is Biofab1?
Who are Ginkgo Bioworks' partners?
What is Ginkgo's role in biosecurity?
How is Ginkgo integrating AI in its operations?
What financial challenges is Ginkgo facing?
How can I stay updated with Ginkgo Bioworks' latest news?
When is Ginkgo's next financial update?
